Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Qualigen Therapeutics Inc QLGN

Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.


NDAQ:QLGN - Post by User

Bullboard Posts
Post by dmacdon Feb 10, 2019 5:31pm
150 Views
Post# 29344427

Does Ritter Understand What is Has in RP-G28 ???

Does Ritter Understand What is Has in RP-G28 ???https://hotcopper.com.au/threads/imc-alcoholic-steatohepatitis-ash-trial.4630233/

I am wondering if Ritter and Immuron should be talking to each other? I would love to see some testing done with these two in tandem with each other, and at the least sign an NDA with each and explore the concept with some animal studies. Ritter might have more value than we investors currently understand if my hunch is right ... or is that my gut ... lol. 

It seems as though it might also help with their C-Diff trials as well, unless these drugs are acting on similar mechanisms. I do not know enough on the topic but definitely there are some synergies to explore. 

Perhaps IMM-124E needs the gut bacteria to be high enough to be more broadly effective. IMM-124E comes from cows (colostrum) that were forced to generate anti-inflammatory anti-bodies. 

Dr Arun Sanyal is the lead for one of the current IMM-124E test. Worthwhile to run some animal tests?
Bullboard Posts